Navigation Links
GENova Biotherapeutics and Prime BioResearch signs LOI on diabetes and cancer cure

NEW YORK, NY, Sept. 15 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova") today announced it has signed an LOI with Prime BioResearch, Ltd. ("Prime BioResearch"), another drug acquisition company in the areas of drug development and distribution a business case that will save GENova millions every year in drug development and at the same time more than double GENova's distribution network enabling GENova to potentially exceed its own expectations of reaching 100m+ in revenue in year 3

GENova and Prime BioResearch will collaborate to share best practices, scientific expertise and to leverage their mutual networks of global bioscience Research and Development organizations and drug distribution channels.

The two companies are both in the business of acquiring early-stage developmental drugs, and out-licensing them for development and commercialization, and garnering royalty payments in the process. GENova's focus is oncology, while Prime BioResearch specializes in Obesity, Type 2 Diabetes and other metabolic disorders.

"While Prime BioResearch aims to cure metabolic disorders, and GENova seeks cancer cures, our two companies have much in common, and we can learn a lot from each other and help each other towards success," says Aaron Whiteman, CEO for GENova.

Both companies share a mutual goal of fast-tracking their target drugs through development, clinical studies, licensing to Large Pharma Companies, and finally to market. Navigating the myriad of channels to do so can be complex, and so by sharing strategies in efficiency, both GENova and Prime BioResearch will mutually benefit. The ultimate goal is to get their promising anti-cancer and anti-obesity drugs to market as soon as possible.

About Prime BioResearch

Prime BioResearch Ltd. is in the business of identifying, evaluating and acquiring potential blockbuster developmental drugs in medical markets with significant growth potential. Prime BioResearch currently has a proprietary portfolio of six worldwide patents in Obesity and Diabetes-II worth $2.9 billion, if successfully brought through development, clinical trials, and to market (Source: PriceWaterhouseCoopers). The Company's mission is to make safe and effective drugs available to the public, quickly and at affordable levels.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at:

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GENova gains access to Big Pharma
2. GENova appoints Dr. Wang Chong to Scientific Advisory Board
3. GENova appoints Dr. Philip Gould to Scientific Advisory Board
4. GENova issues clarifying press release
5. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
6. GENova files patent for new breast cancer treatment
7. GENova appoints Director of Asian business development
8. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
9. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
10. Genova files patent for new prostate cancer treatment
11. GENova names Dr. John Savin as Vice President
Post Your Comments:
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from reveals that behind ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: